Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-043488
Filing Date
2025-03-24
Accepted
2025-03-24 07:04:58
Documents
6
Effectiveness Date
2025-03-24

Document Format Files

Seq Description Document Type Size
1 S-8 lxeo_s-8_evergreen_2025.htm S-8 153815
2 EX-5.1 lxeo-ex5_1.htm EX-5.1 13981
3 EX-23.1 lxeo-ex23_1.htm EX-23.1 16588
4 EX-FILING FEES lxeo-exfiling_fees.htm EX-FILING FEES 27993
5 GRAPHIC img155268912_0.jpg GRAPHIC 321697
6 GRAPHIC img238985936_0.jpg GRAPHIC 29651
  Complete submission text file 0000950170-25-043488.txt   697494
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286040 | Film No.: 25762200
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)